Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

First International Summit on Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Deborah Collyar: What's In It for Patients?

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Apr

Today In Oncology

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Deborah Collyar: What's In It for Patients?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

LuPSMA-617 and Pembrolizumab in mCRPC

Is Standard of Care Optimal for the Individual Patient?

ASH-ISTH Create Guidelines for Pediatric VTE Prophylaxis

Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers

New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia